Navigation Links
Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
Date:1/12/2009

p>

Bradbury added, "Our priorities are clear: Grow BYETTA and SYMLIN revenue, submit the NDA for exenatide once weekly and maintain an unwavering focus on managing expenses to achieve positive cash flow by the end of 2010."

A recording of the presentation is accessible through Amylin's corporate Web site, located at www.amylin.com.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Amylin's actual results could differ materially from those discussed due to a number of risks and uncertainties, including the risks that: BYETTA and SYMLIN and the revenues generated from these products may be affected by competition, unexpected new data, and safety and technical issues; clinical trials, including those mentioned in this press release, not being completed in a timely manner, confirming previous results, or achieving the intended clinical endpoints; label expansion requests or NDA filings, including those mentioned in this press release, not being submitted in a timely manner; regulatory approvals being delayed or not received; updates to the BYETTA label not being finalized in a timely m
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... , ... Costello served as Lead Levee Design Engineering Manager for a feasibility ... area from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... for providing protection, Costello also balanced socio-economic and environmental needs and concerns. ...
(Date:7/28/2015)... 29, 2015 A ... rapidly developing and commercialising innovative medicines to transform ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality ... c. £76.5m), gross, from blue chip institutional investors and ...
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
(Date:7/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) has ... and Freezers Market - Global Industry Analysis, Size, ... report to their offering. ... been segmented based on applications: hospitals, research laboratories, ... others segment includes applications of biomedical refrigerators and ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3
... Vaccinogen, Inc. announced that,its new vaccine to ... in Europe starting June 2008., "This makes ... cancer," said Dr. Michael G. Hanna, Jr., Ph.D., ... of our worldwide strategy of profitable,distribution. Questions of ...
... ROCK, Ark., Feb. 27 Cauley Bowman Carney ... acquisition of,CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI ). ... entered into a definitive merger agreement,with an affiliate ... the proposal,CollaGenex,s shareholders would receive $16.60 per share ...
... COLLECTION, PROCESSING AND STORAGE OF EQUINE ... PLACENTAL TISSUE STEM CELLS, RANCHO CORDOVA, Calif., Feb. ... supplier of innovative products and,services that process and store ... Inc., has signed a formal agreement with,the UC Davis ...
Cached Biology Technology:Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 3ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 4ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 5
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... North Hollywood, CA August 13, 2009 - The ... and support for myeloma patients, families, researchers and physicianstoday ... link between environmental toxins and bone disease in multiple ... of cells in the bone marrow that affect production ...
... the splendidly colorful leaves adorning the trees are a delight ... yellow, while the United States and East Asia boast lustrous ... differences in autumnal hues around the world? A new theory ... Education- Biology at the University of Haifa-Oranim and Prof. Jarmo ...
... deaths has declined steadily in the last three decades. ... age groups have shown some improvement, according to a ... of the American Association for Cancer Research. ... better treatment, have resulted in profound gains, but these ...
Cached Biology News:New study suggests possible genetic links between environmental toxins and multiple myeloma 2Why are autumn leaves red in America and yellow in Europe? 2Why are autumn leaves red in America and yellow in Europe? 3Cancer mortality rates experience steady decline 2
... Kit is designed for fast and easy ... cells and tissues. The bead beating technology ... isolation procedures such as CTAB, phenol, or ... precipitation is not necessary - purified DNA ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
... The ApopTag Fluorescein Direct ... detects apoptotic cells in situ ... The DNA fragments are tagged ... nucleotide. The kit provides fluorescence ...
... APO-BRDU Kit is a two ... and total cellular DNA to detect apoptotic ... contains the instructions and reagents required for ... negative control cells for assessing reagent performance; ...
Biology Products: